The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TIDAL: A phase II study of the DLL3-directed T-cell engager tarlatamab in DLL3-positive metastatic prostate cancer.
 
Karen Autio
Honoraria - MashupMedia
Consulting or Advisory Role - Fusion Pharmaceuticals; VIR Biotechnology
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst); Janssen (Inst); Janux Therapeutics (Inst); Pfizer (Inst)
 
William Kelly
Honoraria - Amgen; Janssen Oncology
Consulting or Advisory Role - Amgen; Bayer; Fusion Pharmaceuticals; Janssen Oncology
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Kevin Zarrabi
Honoraria - Aptitude Health; Association of Community Cancer Centers (ACCC); Curio Science; OncLive Clinical Congress Consultants
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai; Exelixis; Johnson & Johnson/Janssen; Pfizer; Survivornet
Research Funding - 858 Therapeutics (Inst); Amgen (Inst); DualityBio (Inst); Exelixis (Inst); IDEAYA Biosciences (Inst); Johnson & Johnson/Janssen (Inst); Vaccitech (Inst)
Travel, Accommodations, Expenses - Janux Therapeutics; Telix Pharmaceuticals
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Precede Bio; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Glenn Heller
No Relationships to Disclose
 
Mark Dunphy
Patents, Royalties, Other Intellectual Property - Memorial Sloan Kettering Cancer Center holds the intellectual rights to PU-H71 and [124I]-PU-H71 (PCT/US06/03676, PCT/US2012/045861), which have been licensed to Samus Therapeutics. Dr. Dunphy has contributed to the patents and has received financial roya
 
Salomon Tendler
Patents, Royalties, Other Intellectual Property - 18/589,762; SK2021-128-03; ANTI-DLL3 ANTIBODIES AND USES THEREOF
 
Jason Lewis
Leadership - pHLIP
Stock and Other Ownership Interests - Alpha-9; Clarity Pharmaceuticals; Evergreen Theragnostics; HoneyBear Biosciences; pHLIP; Summit Biomedical Imaging; Telix Pharmaceuticals
Consulting or Advisory Role - Alpha-9; BicycleTX Limited; Clarity Pharmaceuticals; InhibRx; Invicro; ITM Isotopen Technologien Munchen; Molecular Partners; Precirix; Wren Laboratories, LLC
Research Funding - Clarity Pharmaceuticals; Novartis
Patents, Royalties, Other Intellectual Property - Clarity Pharmaceuticals; Daiichi Sankyo; Elucida Oncology, Inc; Macrocyclics, Inc; Theragnostics, Ltd
 
Insiya Neemuchwala
No Relationships to Disclose
 
Bhanuteja Yandrapalli
No Relationships to Disclose
 
Kendall Garrett
No Relationships to Disclose
 
Jodi-Ann McDonald
No Relationships to Disclose
 
Kristina Dushaj
No Relationships to Disclose
 
Michael Morris
Employment - Memorial Sloan-Kettering Cancer Center
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Advancelle; Amgen; ARTbio; Arvinas; Bristol-Myers Squibb; Convergent Therapeutics; Exelixis; Flare Therapeutics; Fusion Pharmaceuticals; Isotopia; Lantheus Medical Imaging; Mashup Media; Molecular Partners; Soffinova; Transtherabio; Wren Laboratories; Z-Alpha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Abbvie; APCCC; Memorial Sloan-Kettering Cancer Center
(OPTIONAL) Uncompensated Relationships - Amgen; Bayer; Halda Therapeutics; Janssen Oncology; Novartis
 
Rahul Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; Curio Science; EcoR1 Capital; Exelixis; Flare Therapeutics; Guidepoint Inc; Harpoon therapeutics; Janssen; Merck; MJH Life Sciences; Novartis; PCCTC; Pfizer; Research to Practice; Slingshot Insights; Tersera; Washington Research Foundation
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology